SRC kinase activator CDCP1 promotes hepatocyte growth factor–induced cell migration/invasion of a subset of breast cancer cells

Naoyuki Kawase, Atsuya Sugihara, Kentaro Kajiwara, Michio Hiroshima, Kanako Akamatsu, Shigeyuki Nada, Kunio Matsumoto, Masahiro Ueda, and Masato Okada

From the 1Department of Oncogene Research, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan; 2Laboratory for Cell Signaling Dynamics, RIKEN Center for Biosystems Dynamics Research, Saita, Osaka, Japan; 3Laboratory of Oncogene Research, World Premier International Immunology Frontier Research Centre, Osaka University, Suita, Osaka, Japan; 4Division of Tumor Dynamics and Regulation, Cancer Research Institute, Kanazawa University, Kanazawa, Japan; 5Laboratory of Single Molecule Biology, Graduate School of Frontier Biosciences, and 6Center for Infectious Disease Education and Research, Osaka University, Suita, Osaka, Japan

Cancer invasion and metastasis are the major causes of cancer patient mortality. Various growth factors, including hepatocyte growth factor (HGF), are known to promote cancer invasion and metastasis, but the regulatory mechanisms involved are not fully understood. Here, we show that HGF-promoted migration and invasion of breast cancer cells are regulated by CUB domain–containing protein 1 (CDCP1), a transmembrane activator of SRC kinase. In metastatic human breast cancer cell line MDA-MB-231, which highly expresses the HGF receptor MET and CDCP1, we show that CDCP1 knockdown attenuated HGF-induced MET activation, followed by suppression of lamellipodia formation and cell migration/invasion. In contrast, in the low invasive/nonmetastatic breast cancer cell line T47D, which had no detectable MET and CDCP1 expression, ectopic MET expression stimulated the HGF-dependent activation of invasive activity, and concomitant CDCP1 expression activated SRC and further promoted invasive activity. In these cells, CDCP1 expression dramatically activated HGF-induced membrane remodeling, which was accompanied by activation of the small GTPase Rac1. Analysis of guanine nucleotide exchange factors revealed that ARHGEF7 was specifically required for CDCP1-dependent induction of HGF-induced invasive ability. Furthermore, immunofluorescence staining demonstrated that CDCP1 coaccumulated with ARHGEF7. Finally, we confirmed that the CDCP1-SRC axis was also crucial for HGF and ARHGEF7-RAC1 signaling in MDA-MB-231 cells. Altogether, these results demonstrate that the CDCP1-SRC-ARHGEF7-RAC1 pathway plays an important role in the HGF-induced invasion of a subset of breast cancer cells.

* For correspondence: Masato Okada, okadam@biken.osaka-u.ac.jp.
CDCP1 promotes HGF-induced invasion via ARHGEF7-RAC1 axis

transcriptionally induces invasive properties, such as the production of matrix metalloproteases (12). However, CDCP1’s requirement for HGF-induced invasion and metastasis of human cancer cells was undetermined. Furthermore, the contribution of pathways other than the MET-STAT3 axis needs to be investigated.

To address the above issues, we used the metastatic human breast cancer cell line MDA-MB-231, which has abundant MET and CDCP1 expression, and a low invasive/non-metastatic breast cancer cell line T47D, which has no detectable expression of both mentioned proteins, as model systems. We demonstrated that CDCP1 promoted HGF-induced migration and invasion of breast cancer cells. A mechanistic analysis further revealed that CDCP1 activated the ARHGEF7-RAC1 axis to promote HGF-induced cytoskeleton and membrane remodeling, a prerequisite for cell migration and invasion. These findings shed light on the function of CDCP1 in regulating HGF-MET signaling in cancer invasion and metastasis.

Results

CDCP1 is required for HGF-promoted cell migration and invasion in human breast cancer cell line MDA-MB-231

To verify the importance of CDCP1 in HGF-induced invasion of human cancer cells (Fig. 1A), we used human triple-negative breast cancer cell lines, which highly expressed CDCP1 (19, 20) (Fig. 1B). Among these, we focused our analysis on the cells with the most abundant expression of MET, the metastatic MDA-MB-231 cell line. We first knocked down CDCP1 using siRNA and examined its effects on HGF signaling (Fig. 1C). Immunoblot analysis showed that CDCP1 knockdown significantly decreased MET protein levels even before HGF stimulation (Fig. 1, C and E). Consequently, MET activation was significantly attenuated in the initial phase of HGF signaling (Fig. 1, D and F). Since CDCP1 knockdown did not affect MET mRNA expression (Fig. S1A), it is suggested that CDCP1 functionally interacts with MET and may contribute to the regulation of stability and/or turnover rate of MET protein in these cancer cells.

We then investigated the role of CDCP1 in HGF-induced cell migration and invasion by observing the HGF-induced formation of the lamellipodium, an actin-enriched membrane structure at the leading edge of cells that functions to pull cells forward during migration (21). The HGF-induced formation of lamellipodia was inhibited by CDCP1 knockdown and rescued by CDCP1 re-expression (Fig. 2, A and B). Of note, some CDCP1 coaccumulated with F-actin along the edge of lamellipodia in HGF-stimulated cells (Fig. 2A). Furthermore, Boyden chamber assays revealed that CDCP1 knockdown significantly inhibited HGF-induced cell migration (Fig. 2C) and invasion (Fig. 2D). Furthermore, the inhibition of invasive activity was also rescued by CDCP1 re-expression (Fig. 2D). These observations suggest that CDCP1 is required for HGF-induced dynamic cell migration and invasion in MDA-MB-231 cells.

CDCP1-SRC promotes HGF-induced cell invasion in human breast cancer cell line T47D

To further confirm the role of CDCP1 in HGF signaling, we subsequently employed a low invasive/nonmetastatic breast cancer cell line T47D, which had no significant expression of either protein (Fig. 1B) and no invasive activity (Fig. S1, B and C). We thus introduced MET into these cells using a Tet-On system and then established cell lines with or without stable CDCP1 overexpression. Effects of CDCP1 expression on HGF signaling were examined using immunoblot analysis (Fig. 3A). MET expression enabled these cells to respond to HGF stimulation, as indicated by the phosphorylation of MET, AKT, and ERK. Since MET was forcedly and continuously overexpressed in the distinct cell lines, the effects of CDCP1 expression on MET protein levels and cell signaling could not be accurately compared. Consequently, MET signaling (e.g., p-ERK1/2) appeared unchanged or rather decreased by CDCP1 expression (Fig. 3, A and B). Nonetheless, CDCP1 expression induced a 2- to 3-fold increase in SRC-pY416 signals, indicating that SRC was selectively activated by CDCP1 expression (Fig. 3B). Under these conditions, the invasion assay using the Boyden chamber showed that HGF-induced invasive activity was enhanced by CDCP1 expression, but the expression of a mutant CDCP1 that lacks SRC activation site (CDCP1-Y734F) (12) failed to promote HGF-induced invasion (Fig. 3, C–E). These results suggest that the CDCP1-SRC axis is involved in the promotion of HGF-induced cell invasion.

CDCP1-SRC promotes HGF-induced membrane ruffling in T47D cells by activating RAC1

Since T47D cells retained epithelial features, even though they overexpressed both MET and CDCP1, HGF stimulation was unable to promote lamellipodia formation. Thus, we observed effects of HGF stimulation on membrane dynamics in these cells. Time-lapse microscopy analysis revealed that CDCP1 expression dramatically enhanced the formation of membrane ruffles, which were enriched with the actin cytoskeleton (Movie S1–S4 and Fig. 4, A and B). Membrane ruffles and lamellipodia are known to be formed via RAC1-GTPase-mediated reorganization of the actin cytoskeleton (22). Inhibitor analysis in MET-expressing T47D cells indicated that CDCP1-dependent promotion of invasion activity was markedly suppressed by an inhibitor of RAC1 (Fig. S2A). The treatment with a phosphotyidylinositol 3-kinase (PI3K) inhibitor LY294002 or a Src family kinase (SFK) inhibitor Dasatinib significantly inhibited the basal invasion activity, indicating the requirement of PI3K and SFK activities for promotion of cell invasion (Fig. S2, A and B). Furthermore, a pull-down assay for RAC1 activity showed that CDCP1 expression significantly enhanced HGF-dependent RAC1 activation (Fig. 4, C and D).

The roles of RAC1 and SRC in CDCP1-dependent promotion of HGF-induced cell invasion was further confirmed in MDA-MB-231 cells. HGF-induced lamellipodia formation was inhibited by RAC1 inhibitor but not by ROCK inhibitor.
Y27632 (Fig. S2C). The treatment with Dasatinib strongly suppressed cell invasion, and RAC1 inhibitor treatment suppressed HGF-dependent promotion of cell invasion (Fig. S2). Re-expression of wild-type CDCP1 significantly restored HGF-dependent invasive activity in CDCP1 knockdown cells, whereas that of CDCP1-Y734F only partially rescued the phenotype (Fig. S2D). Furthermore, Dasatinib treatment significantly suppressed HGF-induced RAC1 activation (Fig. S2, E and F). Although the sensitivity to inhibitors was somehow different between the two cell lines, these data underscore the role of RAC1 and the CDCP1-SRC axis in HGF-induced invasion activity and raise a question of how the CDCP1-SRC axis activates RAC1.

**ARHGEF7 is critical for CDCP1-dependent promotion of cancer cell invasion**

Since CDCP1 does not contain a structure that has the activity of guanine nucleotide exchange factor (GEF), we hypothesized that some RAC1 GEFs mediate the functional
interplay between CDCP1 and RAC1. To explore this possibility, we knocked down several RAC1 GEFs, including ARHGEF7, VAV2, TIAM1, and DOCK1, which have been implicated in membrane ruffling (22–26) (Fig. S3A), and examined effects on CDCP1-dependent promotion of HGF-induced invasive activity in MET-expressing T47D cells (Fig. S3B). Among the GEFs tested, only ARHGEF7 knockdown suppressed CDCP1-dependent activation of invasive activity. Knockdown of other GEFs suppressed the invasive activity independent of CDCP1. The rescue experiment using the shRNA-resistant ARHGEF7-mCherry construct (res-ARHGEF7) in MET-expressing T47D cells clearly revealed that ARHGEF7 re-expression restored CDCP1-dependent promotion of HGF-induced invasive activity (Fig. 5, A–C). Furthermore, ARHGEF7 knockdown completely suppressed CDCP1-dependent RAC1 activation (Fig. 5, D and E), which was restored by res-ARHGEF7 expression (Fig. 5, F and G).

To validate the role of ARHGEF7, we knocked down ARHGEF7 and/or CDCP1 in MDA-MB-231 cells and examined their effects on HGF-induced invasive activity (Fig. 6). The results showed that ARHGEF7 was required for CDCP1-dependent promotion of HGF-induced invasive activity (Fig. 6, A and B) and other GEFs functioned independently of HGF signaling in these cells as well (Fig. S4, A and B). Furthermore, knockdown of ARHGEF7 and/or CDCP1 significantly suppressed HGF-induced RAC1 activation (Fig. 6, C and D) and lamellipodia formation (Fig. 6, E and F). Taking these findings together with the fact that SRC activity was required for HGF-induced RAC1 activation (Fig. S2, E and F), it is likely that HGF-induced RAC1 activation by CDCP1-SRC is
preferentially dependent on ARHGEF7, raising the next question of how the CDCP1-SRC axis activates ARHGEF7.

**CDCP1 potentiates HGF-induced accumulation of ARHGEF7 on PIP3-enriched membrane domain**

To elucidate the functional link between the CDCP1-SRC axis and ARHGEF7, we first examined the physical interactions between CDCP1 and ARHGEF7. However, a coimmunoprecipitation assay revealed that there was no stable interaction between these molecules. Furthermore, SRC-induced tyrosine phosphorylation of ARHGEF7 (27) was undetectable under our conditions. Thus, we investigated the subcellular localization of these molecules. Considering that ARHGEF7 has a PH domain (Fig. 7A), we hypothesized that ARHGEF7 can accumulate in the membrane region where
CDCP1 promotes HGF-induced invasion via ARHGEF7-RAC1 axis

PIP3 is enriched. Indeed, immunofluorescence analysis revealed that, upon HGF stimulation, ARHGEF7 accumulated in the membrane region where PH-Btk-EGFP, a PIP3 reporter (28–30), accumulated (Fig. 7B). Furthermore, HGF stimulation induced coaccumulation of ARHGEF7 with CDCP1 at the edge of cells where membrane ruffling occurred in T47D cells expressing MET (Fig. 7C). The HGF-dependent coaccumulation of ARHGEF7 with CDCP1 was also observed at the edge of lamellipodia in MDA-MB-231 cells (Fig. 7D). Furthermore, HGF-induced coaccumulation of ARHGEF7 with CDCP1 was prevented by inhibiting MET (Fig. S5, A and B). Taking these observations together with the contribution of PI3K to HGF signaling (Fig. S2A), it is suggested that the CDCP1-SRC axis potentiates HGF-induced formation of the PIP3-enriched membrane domain, where CDCP1 and ARHGEF7 coaccumulate to activate RAC1-mediated membrane ruffling.

Membrane localization of CDCP1 and MET is regulated via the endosome system

Finally, we addressed how CDCP1 translocates to PIP3-enriched regions. To this end, we examined changes in the subcellular localization of CDCP1 and MET after HGF stimulation using immunofluorescence analysis (Fig. 8). Upon HGF stimulation, both proteins were rapidly endocytosed and colocalized on endosomes within 30 min after stimulation (Fig. 8, A and B). Pretreatment with Dynasore suppressed the endocytosis of both proteins, indicating that the process was clathrin dependent (Fig. 8, C and D). These observations
sugest that CDCP1 interacts with MET during endocytosis. Furthermore, immunofluorescence analysis using endosome markers revealed that CDCP1 accumulated in Rab7-positive late endosomes, and a substantial part of CDCP1 was detected on Rab11a-positive slow recycling endosomes (Fig. 9, A and B). We also observed that tyrosine phosphorylation of CDCP1 gradually (~60 min) increased concurrently with HGF-induced RAC1 activation and membrane ruffling (Fig. S6). These results suggest that activated CDCP1-SRC can be recycled back to the plasma membrane after HGF stimulation. Indeed, immunoblot analysis showed that CDCP1 protein levels were unchanged during HGF stimulation, while activated MET was rapidly degraded via lysosome or proteasome digestion (31) (Fig. 1D). These findings raise the

**Figure 5. ARHGEF7 is critical for CDCP1-dependent promotion of HGF-induced cell invasion in T47D cells expressing MET.**

- **A**, T47D cells expressing MET with or without CDCP1-myc were transfected with shControl or shARHGEF7#1, and the cells treated with shARHGEF7#1 were further transfected with or without shRNA-resistant ARHGEF7-mCherry construct (res-ARHGEF7). ARHGEF7 expression was confirmed by immunoblot analysis. **B**, T47D cell lines used in the above experiments were subjected to a Boyden chamber invasion assay. The scale bar represents 1 mm and 200 μm (inset). **C**, relative number of invaded cells. **D**, T47D cells expressing MET with or without CDCP1-myc were transfected with shControl or shARHGEF7#1. After HGF stimulation for the indicated time, the activity of RAC1 was determined by a pull-down assay. **E**, quantification of RAC1 activity. **F**, the cell lines used in (D) were further transfected with res-ARHGEF7 and analyzed for RAC1 activity. **G**, quantification of RAC1 activity. In (C, E, and G), the mean ratios ± SD were obtained from three/four independent experiments. *p < 0.05; n.s., not significantly different; unpaired two-tailed t test.
CDCP1 promotes HGF-induced invasion via ARHGEF7-RAC1 axis

possibility that activated CDCP1-SRC, which is selectively recycled back to the plasma membrane, contributes to forming the PIP3-enriched region where the ARHGEF7-RAC1 axis is activated.

Discussion

We investigated the role of CDCP1 in human breast cancer cells and found that the CDCP1-SRC axis enhanced the HGF-induced formation of lamellipodia or membrane ruffles, leading to the promotion of cell migration and invasion. A mechanistic analysis revealed the ARHGEF7-RAC1 axis as a novel mediator of CDCP1-dependent promotion of cancer cell invasion. Furthermore, we showed that CDCP1 and ARHGEF7 coaccumulate via the endosome system on the HGF-induced PIP3-enriched membrane domain. These results led us to propose the following working hypothesis (Fig. 9C): HGF stimulation activates PI3K to induce a PIP3-enriched

Figure 6. ARHGEF7 is critical for CDCP1-dependent promotion of HGF-induced cell invasion in MDA-MB-231 cells. A. MDA-MB-231 cells were treated with the indicated siRNAs, and cell lysates were subjected to immunoblot analysis for ARHGEF7 and CDCP1 and MET. B. MDA-MB-231 cell lines used in the above experiments were subjected to a Boyden chamber invasion assay, and relative numbers of invaded cells were shown. C. MDA-MB-231 cell lines transfected with the indicated siRNAs were treated with HGF for the indicated time, and the activity of RAC1 was determined by a pull-down assay. D. Quantification of RAC1 activity. E. MDA-MB-231 cells were treated with the indicated siRNA and then stimulated with HGF for 6 h. Cells were subjected to immunofluorescence staining for F-actin. Yellow arrowheads indicate lamellipodia. The scale bar represents 10 μm. F. Ratio of the length of lamellipodia to that of total peripheral membrane. In (B, D, and F), the mean ratios ± SD were obtained from three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001; unpaired two-tailed t test.
membrane domain, known as lipid rafts. Lipid raft-localized CDCP1 activates SRC, which can directly/indirectly promote the PI3K activation (32). CDCP1-SRC can also activate MET to potentiate HGF signaling (12). By linking these signaling circuits, CDCP1 may accelerate the local formation of PIP3-enriched signaling platform, where ARHGEF7 accumulates.
CDCP1 promotes HGF-induced invasion via ARHGEF7-RAC1 axis

to activate RAC1-mediated membrane ruffling/lamellipodia formation. As reported previously (12), CDCP1 also contributes to the upregulation of gene expression required for invasive properties, such as matrix metalloprotease production, by activating the Src-STAT3 axis. Activating these multiple pathways promoted cell migration and invasion synergistically. This model sheds new light on the regulatory mechanism of HGF-MET signaling, which promotes cancer invasion and metastasis.

ARHGEF7, also known as Cool-1 and βPix, is an essential Dbl family of Rac GTPase GEF implicated in cytoskeleton remodeling, which is important in cell migration (33–35). In cancers, it has been shown that ARHGEF7 affects the motility of cancer cells in vitro and invasion in vivo (36, 37). Interestingly, the ARHGEF7 gene is frequently amplified in metastatic lesions rather than at primary sites in colorectal adenocarcinoma (38). The Cancer Genome Atlas database analysis revealed that, although there is no significant correlation between CDCP1high groups and poor prognoses in patients with breast cancer, ARHGEF7high groups have a significant correlation with poor prognoses (Fig. S7, A and B). Furthermore, CDCP1high/ARHGEF7high groups show stronger correlation with poor prognoses than other groups (Fig. S7C). These lines of evidence underscore the importance of ARHGEF7 in cancer malignancy. However, their regulatory mechanisms are not fully understood. In this study, we found that HGF-induced and CDCP1-dependent accumulation of ARHGEF7 onto the PIP3-enriched membrane domain triggers the activation of...
RAC1-mediated actin cytoskeleton remodeling, leading to the promotion of cell migration and invasion. Since various growth factors, such as EGF, can activate PIP3 production, it is likely that ARHGEF7 more widely contributes to cancer invasion/metastasis caused by amplification and/or mutation of various growth factor receptors.

We further addressed CDCP1 accumulation in PIP3-enriched membrane regions at the tips of membrane ruffles and lamellipodia. One explanation is that CDCP1 can be retained in PIP3-enriched lipid rafts via two palmitoylation moieties attached just underneath its transmembrane domain (12). Another possibility may be that CDCP1 can be dynamically trafficked via the endosome system. We found that CDCP1 was rapidly endocytosed following HGF stimulation and colocalized with MET at endosomes, where activation of the MET-CDCP1 axis occurs. Activated MET is

---

**Figure 9. CDCP1 is recycled via the endosome system.** A, T47D cells expressing MET and CDCP1-myc were stimulated with HGF for 30 min and subjected to immunofluorescence analysis for CDCP1-myc and the indicated endosome markers. Insets are magnified views. The scale bar represents 10 μm and 2 μm (inset) B, ratios of CDCP1 colocalization with endosome markers. The mean ratios ± SD were obtained from five independent experiments. ***p < 0.001; unpaired two-tailed t test. C, schematic model of our working hypothesis derived from this study.

---

RAC1-mediated actin cytoskeleton remodeling, leading to the promotion of cell migration and invasion. Since various growth factors, such as EGF, can activate PIP3 production, it is likely that ARHGEF7 more widely contributes to cancer invasion/metastasis caused by amplification and/or mutation of various growth factor receptors.

We further addressed CDCP1 accumulation in PIP3-enriched membrane regions at the tips of membrane ruffles and lamellipodia. One explanation is that CDCP1 can be retained in PIP3-enriched lipid rafts via two palmitoylation moieties attached just underneath its transmembrane domain (12). Another possibility may be that CDCP1 can be dynamically trafficked via the endosome system. We found that CDCP1 was rapidly endocytosed following HGF stimulation and colocalized with MET at endosomes, where activation of the MET-CDCP1 axis occurs. Activated MET is
**CDCP1 promotes HGF-induced invasion via ARHGEF7-RAC1 axis**

downregulated via lysosomes or proteasomes, whereas CDCP1 is recycled back to the plasma membrane via recycling endosomes. The differential fates of MET and CDCP1 may be due to differences in their ubiquitination modes, which regulate the sorting of target proteins on the endosome membranes (39). Activated MET is selectively subjected to lysosomal or proteasomal digestion through ubiquitination (5, 31), although the fate determinant mechanism for CDCP1 remains unknown. Taking these pieces of information together, we propose that recycled CDCP1, which is concentrated and activated through the endosome system, may contribute to forming the PIP3-enriched region in the plasma membrane where the ARHGEF7-RAC1 axis is activated. Since CDCP1 can functionally interact with other transmembrane receptors, including HER2, EGFR, and integrin β1 (40, 41), it is possible that CDCP1 is involved in regulating receptor signaling in a manner similar to that of MET.

In conclusion, our studies in breast cancer cell lines identified the CDCP1-SRC-ARHGEF7-RAC1 axis as a crucial mediator of HGF-induced cancer cell migration and invasion. Further extensive investigation of this axis could provide new clues for understanding the mechanism of cell invasion and metastasis induced by various growth factors implicated in cancer malignancy.

**Experimental procedures**

**Cell culture**

MDA-MB-231, T47D, and Hs578T cells were cultured in Dulbecco’s modified Eagle medium containing 10% fetal bovine serum (FBS) at 37 °C with 5% CO₂. BT-549 and HCC-1937 cells were cultured in RPMI1640 medium containing 10% FBS at 37 °C with 5% CO₂. For experiments with HGF stimulation, cells were plated 48 h before HGF treatment. Cells were then serum starved, and 1 mg/ml doxycycline was added for 24 h before adding 100 ng/ml HGF to serum-free medium for varying times. Recombinant human HGF (insect derived) was purchased from PeproTech.

**Antibodies and inhibitor**

The primary antibodies used in this study were Myc-Tag (9B11), CDCP1, Met (D1C2), phospho-Met (Tyr1234/1235) (D26), phospho-tyrosine (P-Tyr-1000), phospho-Src (Tyr416), phospho-Akt (Ser473), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), Vav2 (C64H2), and Rab7 (D95F2) obtained from Cell Signaling Technology. Anti-GAPDH antibody was purchased from Santa Cruz Biotechnology. Anti-EEA1 and Anti-Rac1 antibodies were purchased from BD Biosciences. Anti-M6PR antibodies were purchased from Thermo Fisher Scientific. Anti-ARHGEF7 antibody was prepared by immunizing rabbits with C-terminal fragments. Dynamin inhibitor Dynasore, PI3K inhibitor LY294002, and SFK inhibitor Dasatinib were purchased from Abcam. ROCK inhibitor Y27632 was purchased from Cayman chemical. RAC1 inhibitor was purchased from Merk. MET inhibitors, AMG337 and Crizotinib, were purchased from Selleck Chemicals.

**Immunoblotting and immunoprecipitation**

For Western blotting and immunoprecipitation assays, cells were lysed with RIPA buffer (25 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1% [v/v] NP-40, 0.1% [w/v] SDS, 0.5 mM EDTA, 0.25 mM EGTA, 1% [w/v] sodium deoxycholate, 1 mM NaN₃, 20 mM NaF, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor cocktail) (Nacalai Tesque). For the immunoprecipitation assay, cell lysates were incubated with antibodies at 4 °C. Immunoprecipitated proteins were then pulled down using protein G-Sepharose (GE Healthcare). Horseradish peroxidase–conjugated anti-mouse or anti-rabbit IgG (Zymed Laboratories Inc) was used as the secondary antibody. All immunoblots were visualized and quantitated using a Luminograph II System (Atto).

**Immunofluorescence microscopy**

For two-dimensional culture, cells were grown on coverslips coated with type-I collagen, fixed with 4% paraformaldehyde (PFA), and permeabilized with phosphate-buffered saline (PBS) containing 0.03% Triton X-100. For three-dimensional culture, cysts embedded within the collagen matrix were fixed with 4% PFA and permeabilized with PBS containing 0.5% Triton X-100. Permeabilized cells and cysts were blocked with 1% bovine serum albumin and incubated with primary antibodies, followed by incubation with Alexa Fluor 488/594-phalloidin (Molecular Probes). Immunostained objects were observed using an FV1000 confocal microscope (Olympus Corporation). For time-lapse observations, cells were plated on a glass-bottom dish (IWAKI) and observed using a Ti-E inverted microscope (Nikon).

**Plasmid construction and gene transfer**

cDNA of CDCP1, siRNA-resistant CDCP1, Rab4a, Rab11a, ARHGEF7, shRNA-resistant ARHGEF7, and the PH domain of Btk were generated by PCR using human cDNA as the template and subcloned into the pCX4 retroviral plasmid (generously donated by Dr Akagi). siRNA-resistant CDCP1 and shRNA-resistant ARHGEF7 were generated by mutagenesis PCR. shRNAs against GEFSs-mRNA were generated using PCR and a pLKO.1-shRNA vector and subsequently introduced by lentiviral infection. Detailed information on the primers is provided in Supporting information Table S1. All PCR experiments were performed using KOD-Plus polymerase (Toyobo Co, Ltd). Primer sequences used for mutagenesis and generation of shRNAs are listed in Supporting information Table S2. MET was subcloned into the pRetroX-TRE3G retroviral plasmid (Clontech Laboratories). All constructs were confirmed by sequencing. Gene transfer of pCX4 and pRetroX-TRE3G was carried out by retroviral infection. Retroviral production was performed using Plat-E cells. Lipofection of viral vectors into Plat-E cells was performed using PEI MAX (Polysciences Inc). siRNAs were purchased from Sigma-Aldrich (St Louis) and transfected with Lipofectamine RNAiMAX (Thermo Fisher Scientific). siRNAs used are listed in Supporting information Table S3.
qPCR assay

RNA from MDA-MB-231 was collected with NucleoSpin RNA Plus (MACHERY-NAGEL). Then 1 μg of Collected RNA samples was used for RT-qPCR with ReverTra Ace qPCR Mix (Toyobo Co, Ltd). qPCR assays were performed with QuantStudio 5 (Thermo Fisher Scientific) and THUNDER-BIRD NEXT SYBR qPCR Mix (Toyobo Co, Ltd).

The primers used in MET mRNA quantification are:
- Forward: ACCTTTGATAAATGTTTTGAC
- Reverse: GCATTTAGGCTGCCAGCTTAT

The primers used in GAPDH mRNA quantification are:
- Forward: GCTCTGCTCCTCCTGTTC
- Reverse: CGCCCAAATACGACCAAATCC

GTP-Rac1 pull-down assay

PAK-PBD beads were purchased from Cytoskeleton Inc. Cells were lysed using Rac1 IP buffer (50 mM Tris-HCl [pH 7.5], 10 mM MgCl₂, 0.5 M NaCl, and 2% Nonidet P-40), and the protein concentration was adjusted to 0.5 mg/ml. For the pull-down assay, 800 μl of cell lysate was used for each time point, and 10 μl of PAK-PBD beads was added to each lysate. Bound GTP-Rac1 was detected by Western blotting using an anti-Rac1 antibody (BD Biosciences).

In vitro migration and invasion assay

BioCoat cell culture permeable supports and Matrigel Invasion Chambers (Corning Inc) were used for the migration and invasion assays, respectively. Cells (0.5 × 10⁵ for migration assays and 1 × 10⁵ for invasion assays) were seeded on inserts and invasion assays, respectively. Cells (0.5 × 10⁵ for migration and 1 × 10⁵ for invasion assays) were seeded on inserts and transferred to chambers containing culture media and 0.1% FBS, with or without 100 ng/ml HGF. After incubation at 37 °C for 24 h, migrated or invaded cells were fixed with 4% PFA and stained with 1% crystal violet. Invasive cells were counted. Migration and invasion assays were repeated thrice.

Clinical and gene expression analysis

Clinical and RNA sequencing data of breast cancer (1209 patients) from The Cancer Genome Atlas dataset were used. Survival curves were constructed using the Kaplan–Meier method and compared by using the log-rank test.

Statistics and reproducibility

For data analyses, unpaired two-tailed t tests were performed to determine differences between groups. A two-way analysis of variance (ANOVA) was used for multiple group comparisons. A p-value of <0.05 was considered statistically significant. All data and statistics were derived from at least three independent experiments.

Data availability

All data are contained within the article.

Acknowledgments—We would like to thank Editage (www.editage.com) for English language editing. This work was supported by the Interdisciplinary Program for Biomedical Sciences, Program for Leading Graduate School, Osaka University Grant-in-Aid for interdisciplinary Research, Japan.

Author contributions—N. K., A. S., K. K., and M. O. conceptualization; N. K., A. S., M. H., K. A., and S. N. methodology; N. K., A. S., and K. K. investigation; K. K., M. H., and K. A. resources; N. K. writing – original draft; K. K., M. O., and M. O. writing – review & editing; K. M. and M. U. supervision; N. K., K. K., and M. O. funding acquisition.

Funding and additional information—This work was supported by JSP KAKENHI (Grant numbers 19H03504 and 19H04962 to M. O., 19K07639, to K. K.).

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: CDCP1, CUB domain-containing protein 1; FBS, fetal bovine serum; GEF, guanine nucleotide exchange factor; HGF, hepatocyte growth factor; PFA, paraformaldehyde; PI3K, phosphatidylinositol 3-kinase; PIP3, phosphatidylinositol 3,4,5-trisphosphate; SFK, Src family kinase.

References

1. Nakamura, T., Nishizawa, T., Hagiya, M., Seki, T., Shimomishi, M., Sugimura, A., Tashiro, K., and Shimizu, S. (1989) Molecular cloning and expression of human hepatocyte growth factor. Nature 342, 440–443
2. Gherardi, E., Gray, J., Stoker, M., Perrymann, M., and Furlong, R. (1989) Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. Proc. Natl. Acad. Sci. U. S. A. 86, 5844–5848
3. Weidner, C., Schmelz, M., Schmidt, R., Hansson, B., Handwerker, H. O., and Torobjork, H. E. (1999) Functional attributes discriminating mechano-insensitive and mechano-responsive C nociceptors in human skin. J. Neurosci. 19, 10184–10190
4. Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M., Kmiecik, T. E., Vande Woude, G. F., and Aaronson, S. A. (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802–804
5. Trusolino, L., Bertotti, A., and Comoglio, P. M. (2010) MET signalling: Principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 11, 834–848
6. Borowiak, M., Garratt, A. N., Wustefeld, T., Strehle, M., Trautwein, C., and Birchmeier, C. (2004) Met provides essential signals for liver regeneration. Proc. Natl. Acad. Sci. U. S. A. 101, 10608–10613
7. Nakamura, T., Sakai, K., Nakamura, T., and Matsumoto, K. (2011) Hepatocyte growth factor twenty years on: Much more than a growth factor. J. Gastroenterol. Hepatol. 26, 188–202
8. Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A., and Birchmeier, C. (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376, 768–771
9. Matsumoto, K., Umitzu, M., De Silva, D. M., Roy, A., and Bottaro, D. P. (2017) Hepatocyte growth factor/MET in cancer progression and biomarker discovery. Cancer Sci. 108, 296–307
10. Sierra, J. R., and Tsao, M. S. (2011) c-MET as a potential therapeutic target and biomarker in cancer. Ther. Adv. Med. Oncol. 3, S21–S35
11. Comoglio, P. M., Trusolino, L., and Boccaccio, C. (2018) Known and novel roles of the MET oncogene in cancer: A coherent approach to targeted therapy. Nat. Rev. Cancer 18, 341–358
12. Kajiwara, K., Yamano, S., Aoki, K., Okuzaki, D., Matsumoto, K., and Okada, M. (2021) CDCP1 promotes compensatory renal growth by integrating Src and Met signaling. Life Sci. Alliance 4, e20200832
CDCP1 promotes HGF-induced invasion via ARHGEF7-RAC1 axis

13. Ikeda, J., Oda, T., Iouque, M., Uekita, T., Sakai, R., Okumura, M., Aozasa, K., and Morii, E. (2009) Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci. 100, 429–433

14. Miyazawa, Y., Uekita, T., Hiraoka, N., Fuji, S., Kusugai, T., Kanai, Y., Nojima, Y., and Sakai, R. (2010) CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res. 70, 5136–5146

15. He, Y., Wu, A. C., Harrington, B. S., Davies, C. M., Wallace, S. J., Adams, T., Tamas, P., Solti, Z., Bauer, P., Illes, A., Sipeki, S., Bauer, A., Farago, A., et al. (2016) Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. Oncogene 35, 468–478

16. Turdo, F., Bianchi, F., Gasparini, P., Sandri, M., Sasso, M., De Cecco, L., Forte, L., Casalini, P., Aiello, P., Sfondrini, L., Agresti, R., Carcangiu, M. L., Plantamura, L., Sozzi, G., Tagliaabue, E., et al. (2016) CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. Oncotarget 7, 69649–69665

17. Liu, H., Ong, S. E., Badu-Nkansah, K., Schindler, J., White, F. M., and Feng, Q., Baird, D., Peng, X., Wang, J., Ly, T., Quan, J. L., and Cerione, R. A. (2006) Cool-1 functions as an essential regulatory node for EGF receptor- and Src-mediated cell growth. Nat. Cell Biol. 8, 945–956

18. Kojima, T., Fukuda, M., Watanabe, Y., Hamazato, F., and Mikoshiba, K. (1997) Characterization of the pleckstrin homology domain of Btk as an inositol polyphosphate and phosphoinositide binding domain. Biochem. Biophys. Res. Commun. 236, 333–339

19. Varnai, P., Rother, K. I., and Balla, T. (1999) Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton’s tyrosine kinase pleckstrin homology domain visualized in single living cells. J. Biol. Chem. 274, 10983–10989

20. Rameh, L. E., Arvidsson, A., Carraway, K. L., 3rd, Counillon, A. D., Rathbun, G., Crompton, A., VanRenterghem, B., Czech, M. P., Ravichandran, K. S., Burakoff, S. I., Wang, D. S., Chen, C. S., and Canley, L. C. (1997) A comparative analysis of the phosphoinositide binding specificity of pleckstrin homology domains. J. Biol. Chem. 272, 22059–22066

21. Clague, M. J. (2011) Met receptor: A moving target. Sci. Signal. 4, pe40

22. Arcaro, A., Aubert, M., Espinosa del Hierro, M. E., Khanzada, U. K., Angelidou, S., Tetreau, T. D., Bittermann, A. G., Frame, M. C., and Seckl, M. J. (2007) Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling. Cell Signal. 19, 1081–1092

23. Campa, F., Machuy, N., Klein, A., and Rudel, T. (2006) A new interaction between Abi-1 and betaPIX involved in PDGF-activated actoskeleton reorganisation. Cell Res. 16, 759–770

24. Heidary Arash, E., Song, K. M., Song, S., Shibani, A., and Attisano, L. (2014) Arhgef7 promotes activation of the Hippo pathway core kinase Lats. EMBO J. 33, 2997–3011

25. Omelchenko, T., Rabadan, M. A., Hernandez-Martinez, R., Grego-Bessa, J., Anderson, K. V., and Hall, A. (2014) beta-Pix directs collective migration of anterior visceral endoderm cells in the early mouse embryo. Genes Dev. 28, 2764–2777

26. Wang, H., Han, M., Whetsell, W., Jr., Wang, J., Rich, J., Hallahan, D., and Han, Z. (2014) Tax-interacting protein 1 coordinates the spatiotemporal activation of Rho GTPases and regulates the infiltrative growth of human glioblastoma. Oncogene 33, 1558–1569

27. Huang, Y. H., Lin, W. L., Hou, Y. T., Pu, Y. S., Shun, C. T., Chen, C. L., Wu, Y. Y., Chen, J. Y., Chen, T. H., and Jou, T. S. (2010) Podocalyxin ERBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7. Am. J. Pathol. 176, 3050–3061

28. Munoz-Bellvis, L., Fontanillo, C., Gonzalez-Gonzalez, M., Garcia, E., Iglesias, M., Esteban, C., Gutierrez, M. L., Abad, M. M., Bencoechea, O., De Las Rivas, J., Orfao, A., and Sayagues, J. (2012) Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density single-nucleotide polymorphism arrays. Mod. Pathol. 25, 590–601

29. Goh, L. K., and Sorkin, A. (2013) Endocytosis of receptor tyrosine kinases. Cold Spring Harb. Perspect. Biol. 5, a017459

30. Casar, B., Rimani, I., Kato, H., Shattil, S. J., Quigley, J. P., and Deryugina, E. I. (2014) In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated beta1 integrin and induction of FAK/PI3K/Akt motility signalling. Oncogene 33, 255–268

31. Alajati, A., Guccini, I., Pinton, S., Garcia-Escudero, R., Berrueta, T., Sarti, M., Montani, E., Rinaldi, A., Montemurro, F., Catapano, C., Beretti, F., and Allimonti, A. (2015) Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes tumourzumab resistance in breast cancer. Cell Rep. 11, 564–576